Resistance to trametinib (MEKs inhibitor) treatment via FGFR1-dependent activation of ERKs and AKT was also observed in lung and pancreatic cancer cells with mutated KRAS [61]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.